Australian Clinical Labs Ltd

As of June 30, 2025, Australian Clinical Labs Ltd carries a market capitalization of 544.30M, placing it among publicly traded companies globally. Its enterprise value stands at 813.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Australian Clinical Labs Ltd's next confirmed earnings release is scheduled for February 23, 2027.

As of June 30, 2025, Australian Clinical Labs Ltd has 195.79M shares outstanding.

As of June 30, 2025, Australian Clinical Labs Ltd trades at a trailing price-to-earnings ratio of 16.21. The price-to-sales ratio is 0.71, and the price-to-book ratio stands at 3.18.

As of June 30, 2025, Australian Clinical Labs Ltd trades at an EV/EBITDA multiple of 4.09 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.11 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.94 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 813.86M versus a market cap of 544.30M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Australian Clinical Labs Ltd maintains a current ratio of 0.55, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 168.84, indicating elevated leverage, while an interest coverage ratio of 52.63 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2025, Australian Clinical Labs Ltd posted a return on equity (ROE) of 18.59, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.92 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.29, useful for judging operating efficiency across full business cycles. The company generates approximately 156,627.23 in revenue per employee across its workforce of 4,700.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.90 indicates how many times Australian Clinical Labs Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, Australian Clinical Labs Ltd recorded 15.36M in income tax expense. That works out to an effective tax rate of 31.88, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 48.18M, leaving 32.43M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Australian Clinical Labs Ltd's stock has gained approximately 15.42% over the past 52 weeks. The 50-day moving average sits at 2.82, while the 200-day moving average is 2.36.

Over the twelve months ended June 30, 2025, Australian Clinical Labs Ltd generated 736.15M in revenue and converted that into 32.43M in net income, yielding earnings per share of 0.17. EBITDA reached 198.93M, while operating income came in at 62.88M.

As of June 30, 2025, Australian Clinical Labs Ltd holds 21.44M in cash and equivalents against 290.38M in total debt, resulting in a net debt position of 20.53M. Total book value stands at 171.35M, with working capital of -96.34M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Australian Clinical Labs Ltd posted a gross margin of 82.58, reflecting its pricing power and cost economics. The operating margin of 8.54 and net profit margin of 4.41 provide insight into operational efficiency.

Over the twelve months ended June 30, 2025, Australian Clinical Labs Ltd paid dividends of 0.13 per share. The dividend payout ratio of 75.12 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 32.84, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Australian Clinical Labs Ltd shareholders.

As of June 30, 2025, Australian Clinical Labs Ltd has an Altman Z-Score of 3.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.